Company Filing History:
Years Active: 2016-2019
Title: Caroline Huynh Diep: Innovator in Cancer Therapeutics
Introduction
Caroline Huynh Diep is a prominent inventor based in Minneapolis, MN (US). She has made significant contributions to the field of cancer research, particularly in the development of therapeutic methods and kits. With a total of 2 patents, her work focuses on improving treatment outcomes for patients with pancreatic cancer.
Latest Patents
Caroline's latest patents include innovative methods and kits designed to predict the therapeutic outcomes of BTK inhibitors. These patents detail methods of testing that assess the expression of DPC4 (SMAD4) to identify subjects with pancreatic cancer who are likely or unlikely to respond to treatment with BTK inhibitors. Additionally, her patents cover methods of treating subjects based on their likelihood of responding to these treatments. The patents also identify therapeutic targets for cancers, particularly those with inactivated DPC4 gene or protein. Furthermore, they describe methods for screening new therapeutic agents using these targets, as well as pharmaceutical compositions comprising BTK inhibitors, such as PCI-32765 or its derivatives, for cancer treatment. Kits that facilitate the performance of these methods are also disclosed.
Career Highlights
Caroline Huynh Diep is affiliated with the Translational Genomics Research Institute, where she continues to advance her research in cancer therapeutics. Her work is characterized by a commitment to improving patient outcomes through innovative scientific approaches.
Collaborations
Throughout her career, Caroline has collaborated with notable colleagues, including Haiyong Han and Daniel D Von Hoff. These collaborations have further enriched her research and contributed to the advancement of cancer treatment methodologies.
Conclusion
Caroline Huynh Diep is a dedicated inventor whose work in cancer therapeutics is making a significant impact. Her innovative patents and collaborations highlight her commitment to improving treatment outcomes for patients with pancreatic cancer.